These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 8743042)

  • 21. Heartwatch: a secondary prevention programme in primary care in Ireland.
    Bennett K; Jennings S; Collins C; Boland M; Leahy J; Bedford D; Shelley E
    Eur J Cardiovasc Prev Rehabil; 2008 Dec; 15(6):651-6. PubMed ID: 19177599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy.
    Bangalore S; Messerli FH; Cohen JD; Bacher PH; Sleight P; Mancia G; Kowey P; Zhou Q; Champion A; Pepine CJ;
    Am Heart J; 2008 Aug; 156(2):241-7. PubMed ID: 18657652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incidence of new coronary events in older persons with prior myocardial infarction and systemic hypertension treated with beta blockers, angiotensin-converting enzyme inhibitors, diuretics, calcium antagonists, and alpha blockers.
    Aronow WS; Ahn C
    Am J Cardiol; 2002 May; 89(10):1207-9. PubMed ID: 12008178
    [No Abstract]   [Full Text] [Related]  

  • 24. [Secondary prevention of cardiovascular diseases].
    Schneider CA; Erdmann E
    Internist (Berl); 2004 Jun; 45 Suppl 1():S23-30. PubMed ID: 15148584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of pharmacological treatment on mortality after myocardial infarction in diabetic patients.
    Zuanetti G; Latini R
    J Diabetes Complications; 1997; 11(2):131-6. PubMed ID: 9101399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Current therapies for secondary prevention after myocardial infarction.
    Cannon CE; Smith SC
    Curr Opin Cardiol; 1999 Mar; 14(2):155-60. PubMed ID: 10191975
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specific profile and referral bias of rehabilitated patients after an acute coronary syndrome.
    Cottin Y; Cambou JP; Casillas JM; Ferrières J; Cantet C; Danchin N
    J Cardiopulm Rehabil; 2004; 24(1):38-44. PubMed ID: 14758102
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Secondary prevention following myocardial infarction: evidence from an audit in South Wales that the National Service Framework for coronary heart disease does not address all the issues.
    Underwood P; Beck P
    Qual Saf Health Care; 2002 Sep; 11(3):230-2. PubMed ID: 12486986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials.
    Volpe M; Tocci G; Sciarretta S; Verdecchia P; Trimarco B; Mancia G
    J Hypertens; 2009 May; 27(5):941-6. PubMed ID: 19381108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Secondary prevention of acute coronary syndrome].
    Motomiya T
    J Cardiol; 1999 Mar; 33 Suppl 1():39-43. PubMed ID: 10342135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The beta 1 hyperselectivity in beta-blocker treatment.
    Cruickshank JM
    J Cardiovasc Pharmacol; 1995; 25 Suppl 1():S35-46. PubMed ID: 7752668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Therapeutic measures following acute myocardial infarct: differential use of PTCA, surgery and drugs].
    Noll G; Kaufmann U; Wenzel RR; Lüscher TF
    Schweiz Med Wochenschr; 1996 Feb; 126(5):164-76. PubMed ID: 8685687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is prophylactic treatment after myocardial infarction evidence-based?
    Brotons C; Calvo F; Cascant P; Ribera A; Moral I; Permanyer-Miralda G
    Fam Pract; 1998 Oct; 15(5):457-61. PubMed ID: 9848433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study).
    Reiner Z; Mihatov S; Milicić D; Bergovec M; Planinc D;
    Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):646-54. PubMed ID: 16874158
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Secondary prevention of coronary heart disease in the elderly.
    Dornbrook-Lavender KA; Roth MT; Pieper JA
    Ann Pharmacother; 2003 Dec; 37(12):1867-76. PubMed ID: 14632542
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cardioprotection with drugs. 1: Coronary heart disease].
    Michel D
    Fortschr Med; 1990 Jan; 108(3):40-4. PubMed ID: 1968878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators.
    Vantrimpont P; Rouleau JL; Wun CC; Ciampi A; Klein M; Sussex B; Arnold JM; Moyé L; Pfeffer M
    J Am Coll Cardiol; 1997 Feb; 29(2):229-36. PubMed ID: 9014971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of myocardial reinfarction. Recommendations based on results of drug trials.
    Flaker GC; Singh VN
    Postgrad Med; 1993 Nov; 94(6):94-8, 102-4. PubMed ID: 7901845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study.
    Vittinghoff E; Shlipak MG; Varosy PD; Furberg CD; Ireland CC; Khan SS; Blumenthal R; Barrett-Connor E; Hulley S;
    Ann Intern Med; 2003 Jan; 138(2):81-9. PubMed ID: 12529088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacotherapy following myocardial infarction--a review of current treatment practices.
    Ørn S; Dickstein K
    Expert Opin Pharmacother; 2000 Sep; 1(6):1105-16. PubMed ID: 11249482
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.